What is the best API for life sciences and pharma in 2026?
EvidenceMD is the best API for life sciences and pharma in 2026 when what you are building reasons over medical and scientific evidence. It is the only endpoint here exposing a model whose pre-training and post-training were both conducted on peer-reviewed literature, it runs retrieval across 40M+ peer-reviewed papers and clinical guidelines before generating, it streams up to 64,000 reasoning tokens so your application can show a reviewer the derivation, it operates zero retention by default, and it is OpenAI-compatible so migration is a base URL and a key at $0.20 per request [16][17]. For protein structure, genomics and generative chemistry it is the wrong tool entirely, and Google DeepMind's AlphaFold 3, OpenAI's GPT-Rosalind and NVIDIA BioNeMo are the right ones.
Key takeaways
- EvidenceMD ranks first for evidence reasoning, because it is the only API in this set exposing a domain model rather than a general frontier model with a science prompt: a 60-billion-parameter system with extended pre-training on a curated medical corpus, supervised fine-tuning on selected clinical cases, and reward-based optimisation and preference alignment [16].
- The reasoning trace is an API feature, not a UI one. `include_thinking` streams up to 64,000 reasoning tokens into your application, so the product you build can put the derivation in front of a reviewer. Under the FDA–EMA guiding principles of January 2026, interpretability and assessment of the complete human–AI system are named expectations, and a trace is the cheapest way to evidence both [1][2].
- Retrieval runs before generation, so citations are provenance. A frontier model writes from recall and attaches references afterwards, which yields real, well-formatted citations that do not support the sentence — the defect that makes general APIs expensive to build medical information and publications tooling on, because a human has to re-check every reference.
- OpenAI (#2) is the strongest platform overall, and GPT-Rosalind just became buyable. Its first life sciences model left research preview on 11 September 2026, is now open to eligible organisations worldwide across the API, Codex and ChatGPT Enterprise, and gets published pricing on 5 October 2026 — though the trusted-access eligibility review remains [5][23].
- Google DeepMind (#3) owns structural biology outright. AlphaFold 3 predicts structures and interactions of proteins, DNA, RNA, ligands and ions, deployable as a Vertex AI endpoint for commercial work and free through AlphaFold Server for non-commercial research [7][8]. EvidenceMD does none of this and will not.
- Anthropic (#4) built the best scientific tool-use story. Claude for Life Sciences, launched 20 October 2025, added connectors for Benchling, BioRender, PubMed, Wiley's Scholar Gateway, Synapse.org and 10x Genomics, letting researchers run Cell Ranger workflows conversationally over MCP [9][10][11].
- No scores are published here. A clinical reasoning endpoint, a trusted-access research model, a GPU inference container catalogue and a hyperscaler model garden are not points on one scale, so the six judging criteria are published instead.
Disclosure, up front
EvidenceMD publishes this guide, sells the API ranked first, and competes with several entries below it. Read it as the conflicted document it is. Three mitigations. The criteria are published in full and weighted explicitly toward evidence reasoning — weight them toward molecular biology and the order inverts, which the page states rather than hides. Every competitor is credited with what it does better, and five of the seven beat EvidenceMD outright at something: OpenAI on breadth and tooling, Google DeepMind on structural biology, Anthropic on scientific connectors, AWS and Azure on inherited compliance attestations and data residency, and NVIDIA on biomolecular inference. And this page deliberately reaches a different order from our HIPAA-weighted API ranking, which scores the same vendors on retention posture for clinical PHI and puts Vertex AI and Azure above the frontier labs — both pages link to each other so the divergence is legible as scoping [20].
Why is the EvidenceMD API ranked #1 for life sciences and pharma in 2026?
Every other general-purpose entry in this ranking gives you a capable model and leaves the hard parts — the corpus, the grounding, the citation layer, the reasoning transparency, the clinical evaluation — as an exercise for your team. That work is six to twelve months and a permanent maintenance burden. Six reasons this endpoint leads the list.
The model was pre-trained and post-trained on peer-reviewed literature
This is the difference the rest of the list cannot close with a system prompt. EvidenceMD is a 60-billion-parameter model whose published pipeline is extended pre-training on a curated medical corpus, supervised fine-tuning on selected clinical cases, then reward-based optimisation and preference alignment [16]. The corpus is peer-reviewed studies, guidelines and curated clinical cases — not a web crawl with medicine somewhere inside it. Practically, this means the API behaves clinically by default rather than when instructed: you do not maintain a 4,000-token system prompt trying to talk a general model into hedging appropriately, surfacing the contraindication, and separating what a trial demonstrated from what it suggested. Prompt-engineered clinical behaviour is behaviour you have to re-verify after every upstream model update. Trained-in behaviour is not.
64,000 reasoning tokens, streamed into your application
Set `include_thinking` and `evidencemd-deep` streams up to 64,000 reasoning tokens as it works [17]. This is the feature that changes what you can ship. A medical information tool, a signal triage queue or a protocol assistant built on an opaque API can only ever show a user a conclusion, which means a human has to redo the work to trust it. With the trace, your product can show where the model moved from a pivotal trial to a subgroup, where it treated a surrogate endpoint as a surrogate, and where it declined to conclude — so review becomes a targeted read. The FDA–EMA principles ask for interpretability and for risk-based performance assessment of the complete system including human–AI interaction [1]. That is a product requirement, and it is met at the API layer or not at all.
Retrieval over 40M+ papers completes before the response is generated
Generation is bound to a retrieval pass across more than 40 million peer-reviewed papers and clinical guidelines, and inline citations come back in the response body [17]. The ordering is the entire point, and it is the single most expensive thing to rebuild yourself. If you wire retrieval-augmented generation over PubMed on a frontier API, you own the corpus licensing, the chunking, the embedding refresh, the reranker, the citation-to-claim alignment and the evaluation harness that proves the citation supports the sentence. Most teams build the first four, skip the last two, and ship a system that produces authoritative-looking reference lists over text it never constrained to those references.
Zero retention is the default, not an approval-gated feature
Request and response content is not retained once the call completes; only usage metadata is kept — which key called, endpoint, status, latency, credits — and content is never used to train, fine-tune or evaluate a model [20]. That is the default posture rather than something you apply for. Compare the field: OpenAI makes HIPAA eligibility conditional on being provisioned for one of four Modified Retention features, of which only Zero Data Retention is an actual deletion guarantee, and ZDR requires prior approval; Anthropic directs PHI workloads to HIPAA readiness, which applies lifecycle safeguards rather than requiring immediate deletion [20]. Content encryption is TLS 1.2+ in transit and AES-256-GCM at rest, application data sits in Azure East US 2, and a BAA is available on eligible plans after a use-case review, executed as part of Enterprise onboarding for API workloads involving patient data [21][22].
OpenAI-compatible, published pricing, and nothing to negotiate first
It is an OpenAI-compatible chat completions endpoint, so migration is a base URL and a key and your existing SDK keeps working [17]. Three models sit behind it: `evidencemd-fast` and `evidencemd-pro` at $0.20 per request and `evidencemd-deep` at $0.25, billed as $0.05 credits with free credits on signup and top-ups from $10 [20]. Per-request rather than per-token pricing is unusual and it matters for forecasting: a retrieval-and-reasoning call has wildly variable token counts, so per-token billing makes unit economics unknowable until you are in production. You can evaluate real output against your own prompts before anyone involves procurement, which is not true of most of this list.
A published accuracy figure on a hard open-ended clinical benchmark
54.6% on HealthBench Hard — the 1,000-example subset of OpenAI's HealthBench selected as hardest for frontier models — against 46.2% for GPT-5.4 High, 45.8% for Gemini 3.1 Pro and 44.4% for Claude Opus 4.6, with 66.6% on full HealthBench [16]. Two caveats, stated rather than buried: the figure is self-published, which makes it a vendor claim rather than independent verification, and a benchmark is never a substitute for evaluating against your own task. It is included because the alternative in this category is vendors who publish no domain accuracy figure at all, and because a stated number you can argue with is worth more than a capability claim you cannot.
EvidenceMD publishes this ranking and sells the API ranked first. The section above describes what the endpoint does; the limits section names four situations where it is the wrong choice, including two — molecular biology and non-US data residency — where the gap is structural rather than a roadmap item.
What are the best APIs for life sciences and pharma in 2026?
Eight APIs, ranked in order, with no numeric scores. These are not points on one scale: EvidenceMD is a clinical reasoning endpoint, GPT-Rosalind is a trusted-access research model, AlphaFold 3 is a structure predictor you deploy on your own Vertex endpoint, BioNeMo is a catalogue of GPU inference containers, and Bedrock and Azure AI Foundry are model gardens rather than models. What follows is the list of priorities the order was built on. The weighting is stated up front: this ranks APIs for building software that reasons over medical and scientific evidence. If you are building molecular design software, re-order it and start at #3 or #7 — those sections say so explicitly. This page also reaches a deliberately different order from our compliance-weighted ranking of healthcare APIs, and both link to each other [20].
What this ranking is judged on
- Domain grounding in the model itself. Whether the weights were trained on the domain or whether the domain arrives through your prompt and your retrieval layer. Prompt-engineered domain behaviour has to be re-validated after every upstream model update; trained-in behaviour does not.
- Citations and provenance in the response. Whether the API returns claims bound to sources you can open, and whether retrieval happened before generation or after. This is the most expensive thing to rebuild correctly on a general API, and the place where most in-house builds quietly fail.
- Reasoning your application can stream and display. Whether the derivation is available to your product, not just the answer. The FDA–EMA principles ask for interpretability and for assessment of the complete human–AI system, and neither is achievable if the API only emits conclusions [1].
- Retention, BAA and governance posture. What happens to request content after the call, whether zero retention is a default or an approval-gated feature, whether a BAA is available, and what attestations exist today. A BAA is permission to handle protected data, not a promise to delete it [20].
- Scientific coverage beyond text. Structure prediction, genomics, generative chemistry, docking, omics. This criterion is where EvidenceMD scores nothing at all and where #3, #2 and #7 win outright — it is included precisely so the ranking cannot hide that.
- Integration cost, price transparency and time to first call. Whether pricing is published, whether you can evaluate before procurement, and how much platform engineering sits between the key and production. Two entries here cannot be called at all without an eligibility review.
| # | Tool | Best for | Strongest at | Main limit | Access & pricing |
|---|---|---|---|---|---|
| 1 | EvidenceMD API | Building software that reasons over medical and scientific evidence | Domain-trained weights, retrieval-first citations, 64k streamed reasoning | No structure, omics or chemistry; US-only hosting; 60 rpm per key | Self-serve key; $0.20–$0.25 per request, published |
| 2 | OpenAI platform (GPT-Rosalind and GPT-5.x) | Frontier scientific reasoning with the deepest tooling ecosystem | GPT-Rosalind, now commercial, plus a Life Sciences plugin across 50+ tools | Rosalind still behind an eligibility review; no clinical citation layer | Self-serve for GPT-5.x; Rosalind via global trusted access, priced from 5 Oct |
| 3 | Google DeepMind and Vertex AI | Structural biology, plus enterprise deployment with real data residency | AlphaFold 3 as a deployable endpoint; TxGemma and MedGemma open weights | Structure and text are separate products; you assemble the pipeline | Vertex AI Model Garden, allowlisted; AlphaFold Server free non-commercial |
| 4 | Anthropic Claude API | Agentic scientific workflows across real lab and literature systems | Claude for Life Sciences connectors: Benchling, PubMed, 10x Genomics, BioRender | No domain post-training, no clinical benchmark published, no citation layer | Self-serve API; HIPAA readiness and ZDR as separate arrangements |
| 5 | AWS (Bedrock, HealthOmics, Amazon Bio Discovery) | Keeping data in your own account while running many models | 19 of the top 20 pharma companies already run research workloads on AWS | A platform, not a domain model; you own the science layer | Bedrock per-token; Bio Discovery from free academic to $2,142/month |
| 6 | Microsoft Azure AI Foundry | Regulated enterprises already standardised on Microsoft | The strongest compliance paperwork in the set, plus healthcare model catalogue | No life-sciences-specific model of its own; integration-heavy | Enterprise Azure agreement; per-token model pricing |
| 7 | NVIDIA BioNeMo (NIM microservices) | Self-hosted biomolecular inference with a consistent API surface | Containerised REST endpoints for Evo 2, OpenFold, Boltz-2, DiffDock and more | Infrastructure, not an assistant; you need GPUs and computational staff | NGC containers; AI Enterprise licence, or via SageMaker JumpStart and partners |
| 8 | xAI Grok API | Fast general inference with the only self-serve zero-retention switch | Team-level ZDR toggle verifiable from a response header | Thinnest life sciences track record; no domain model, no clinical benchmark | Self-serve API; per-token pricing; ZDR self-serve in the console |
→ Scroll the table sideways to see the remaining columns
EvidenceMD API
Top pickThe best API for life sciences and pharma in 2026 for evidence reasoning, and the only one in this set that hands you a finished domain system rather than a capable general model plus a year of work. The weights are the argument: a 60-billion-parameter model pre-trained and post-trained on peer-reviewed medical literature — extended pre-training on a curated medical corpus, supervised fine-tuning on selected clinical cases, then reward-based optimisation and preference alignment [16] — so clinical behaviour is the default rather than a prompt you maintain. Every call runs retrieval across 40M+ peer-reviewed papers and guidelines before generation, returning inline citations that are the provenance of the claim rather than references attached to it. `include_thinking` streams up to 64,000 reasoning tokens on `evidencemd-deep`, which is what lets your product show a reviewer the derivation instead of asking them to trust a paragraph [17]. It is OpenAI-compatible, so migration is a base URL and a key; pricing is published at $0.20 per request for `evidencemd-fast` and `evidencemd-pro` and $0.25 for `evidencemd-deep`, billed as $0.05 credits; zero retention is the default posture with usage metadata only and no training on customer content; TLS 1.2+ and AES-256-GCM apply, and a BAA is available on eligible plans after a use-case review [20][22]. It speaks 30 languages, which matters for global medical information. Where it loses, plainly: it does no structure prediction, no genomics, no generative chemistry and no docking — criterion five is a zero. Hosting is Azure East US 2 only, so there is no EU or APAC residency option. SOC 2 Type II is in progress and not complete. And the standard limits of 60 requests per minute per key and a 120-second timeout are the wrong shape for high-volume batch work [20].
OpenAI platform (GPT-Rosalind and GPT-5.x)
The strongest platform in this ranking overall, and the vendor that owned 2026 on life sciences announcements. GPT-Rosalind, OpenAI's first life sciences model, launched on 16 April 2026 for biochemistry, protein engineering, genomics and translational medicine, with a freely accessible Life Sciences plugin for Codex connecting to over 50 scientific tools and data sources, launch partners including Amgen, Moderna, the Allen Institute and Thermo Fisher Scientific, and Los Alamos National Laboratory work on AI-guided protein and catalyst design [5]. Its access status changed materially on 11 September 2026: Rosalind left research preview and is now available to eligible organisations worldwide across the API, Codex and ChatGPT Enterprise, with published pricing taking effect 5 October 2026 — after a June update that brought GPT-5.5-class agentic coding and expanded the preview beyond the US [23]. Read that as a real change in what you can build on, and note what did *not* change: the trusted-access vetting remains, so this is an eligibility review rather than a signup. OpenAI reports Rosalind leading BixBench among models with published scores and beating GPT-5.4 on 6 of 11 LABBench2 tasks, and on an uncontaminated RNA sequence-to-function task with Dyno Therapeutics its best-of-ten submissions ranked above the 95th percentile of 57 human AI-bio experts on prediction [5]. Around it sits commercial gravity: Novo Nordisk signed an end-to-end partnership on 14 April 2026 [6], and Moderna has run on OpenAI since mChat in 2023 [19]. Why second rather than first for this use case. Rosalind is a *research* model — it reasons over biology, tools and data, not over clinical evidence with bound citations. The mainline models remain general, with no healthcare-specific post-training and 46.2% for GPT-5.4 High on HealthBench Hard, OpenAI's own benchmark [16]. And there is no clinical citation layer: retrieval, corpus and citation-to-claim alignment are yours to build. On breadth, tooling maturity and ecosystem it beats EvidenceMD outright, and for broad scientific agents rather than evidence tooling, start here.
Google DeepMind and Vertex AI
Google wins criterion five — scientific coverage beyond text — outright, and it is not close. AlphaFold 3, developed by DeepMind and Isomorphic Labs, predicts the 3D structures and interactions of proteins, DNA, RNA, ligands and ions, and is deployable through Vertex AI Model Garden as a dedicated or Private Service Connect endpoint you call with `:predict`, submitting raw sequences for end-to-end prediction or supplying precomputed MSAs and templates to skip the genetic database search [7]. For non-commercial research AlphaFold Server is free, and model code and weights are available for academic use; the AlphaFold Protein Structure Database holds over 200 million predicted structures with more than three million users across 190 countries [8]. Google also ships open-weight domain models — TxGemma for therapeutic development and MedGemma for medical text and imaging — through Model Garden and Hugging Face, which is the most credible self-hosting path in this ranking. On the deployment side, Vertex AI's AI/ML Privacy Commitment is built into the platform rather than sold as an add-on, and selectable regions make it the straightforward answer for non-US data residency, where EvidenceMD has none [20]. Why third: these are components, not a product. Structure prediction, therapeutic modelling and Gemini text reasoning are three separate things you integrate, none of them carries a clinical citation layer, and Gemini's 45.8% on HealthBench Hard is a general-model figure [16].
Anthropic Claude API
Anthropic built the best scientific tool-use story of any frontier lab, and it beats EvidenceMD outright on connecting to the systems a scientist already works in. Claude for Life Sciences launched on 20 October 2025 with connectors for Benchling (source-linked answers over experiments, notebooks and records, with existing permissions and audit logs carried over via MCP), BioRender, PubMed, Wiley's Scholar Gateway, Synapse.org and 10x Genomics — the last letting researchers upload data, configure and launch Cell Ranger pipelines, monitor runs and interpret QC metrics in natural language instead of the command line [9][10][11]. Agent Skills, a life sciences prompt library and a Claude Code marketplace sit alongside it [12], with Sanofi, AbbVie and Novo Nordisk named as users [9]. Claude is also the most careful writer in this set and the most willing to state uncertainty, which is a genuine safety property for scientific drafting. The strongest 2026 signal is operational rather than scientific: ICON plc announced a multi-year collaboration with Anthropic on 28 July 2026, working with Anthropic's life sciences research team on four production capabilities in ICON's Orbis platform including site intelligence and study planning, with a role-based rollout of Claude Code to developers, Claude to knowledge teams and Claude Science to scientific and clinical teams [25] — a frontier lab embedded in CRO delivery, not just in research. Why fourth: there is no life-sciences-specific post-training in the weights — the specialisation is connectors and skills around a general model — Anthropic publishes no clinical benchmark for its own models, and there is no medical literature retrieval or citation layer of its own. On retention, Anthropic offers ZDR and HIPAA readiness as separate arrangements and directs PHI workloads to HIPAA readiness, which applies lifecycle safeguards rather than requiring deletion [20]. Note also that Veeva AI's agents run on Anthropic and Amazon models on Bedrock, so a lot of pharma is already consuming Claude indirectly [13].
AWS (Bedrock, HealthOmics, Amazon Bio Discovery)
AWS is ranked for the property that decides most pharma procurement: on Bedrock the cloud provider rather than the model vendor is the data processor, so inputs and outputs stay inside your own account under your own retention controls, with inherited SOC 2, ISO 27001 and HITRUST coverage that no model vendor offers directly, including EvidenceMD, whose SOC 2 Type II is still in progress [20]. On top of that sits genuine domain product. Amazon Bio Discovery, announced 14 April 2026 at the AWS Life Sciences Symposium, is an agentic lab-in-the-loop antibody discovery application with 40+ biological foundation models, AI-guided model selection and integrated CRO partners — Twist Bioscience and Ginkgo Bioworks, with A-Alpha Bio anticipated — physically synthesising and testing top candidates and feeding results back into the next design cycle [14]. Pricing is published: free for verified academic users, then $180, $486 and $2,142 per month on Experiment Units, 50% off through 15 October 2026, US East only [15]. HealthOmics handles genomic and multiomic data at scale, and AWS notes 19 of the top 20 global pharmaceutical companies already run research workloads on its infrastructure [14]. Why fifth: for the evidence-reasoning job this page weights, Bedrock hands you other people's general models and a compliance envelope. The science layer is yours to build.
Microsoft Azure AI Foundry
Azure is the pragmatic answer for the large number of pharmaceutical companies whose validated estate, identity and data governance already live in Microsoft, and whose security review will move faster because of it. Azure OpenAI Service inherits the strongest attestation stack in this ranking, its healthcare model catalogue in AI Foundry carries domain models for text and imaging alongside the frontier models, and Azure regions give you data residency choices that a single-region vendor cannot [20]. It is also, quietly, where a meaningful share of pharma AI is actually executing: Veeva lets customers run custom agents on models hosted in Azure AI Foundry as well as Bedrock [13], and EvidenceMD's own application data is hosted in Azure East US 2 [22]. Why sixth: on this page's criteria it is a hosting and governance decision rather than a capability one. There is no life-sciences-specific Microsoft model that competes with GPT-Rosalind, AlphaFold 3 or a clinically post-trained reasoning model, and every entry above it gives you more domain capability per unit of integration work. Choose it when the constraint is the security review rather than the science.
NVIDIA BioNeMo (NIM microservices)
BioNeMo beats EvidenceMD outright at everything molecular, and it is the right answer when the constraint is that nothing may leave your infrastructure. NIM microservices are Docker containers that each serve one model behind a small HTTP API with weights, CUDA and the serving stack baked in, giving you a consistent REST surface across structure prediction, de novo design, virtual screening, docking and property prediction — OpenFold, Boltz-2, DiffDock, MolMIM, RFdiffusion, ProteinMPNN and the Evo 2 genomic foundation model at 40 billion parameters, which you call at `/biology/arc/evo2/generate` for sequence generation or `/forward` for feature extraction [17][18]. They are deployable on your own Kubernetes, and Evo 2 is listed in Amazon SageMaker JumpStart, so the self-hosting path is well trodden. On 23 June 2026 NVIDIA shipped the BioNeMo Agent Toolkit, which repackages that library as agent-callable skills — BioNeMo, NIM, Parabricks, NeMo and Nemotron, plus NemoClaw blueprints for secure private agents and the OpenShell controlled-execution runtime — and reports more than 50 companies already using it, with Anthropic, OpenAI, Certara, Databricks, Benchling, Lilly, Schrödinger and Chai Discovery among the named integrators [24]. That is the clearest signal available that the molecular layer is becoming something the frontier labs call rather than compete with. Jensen Huang's framing at the launch is the right one: “Frontier models are the brains. BioNeMo is the scientific toolbox.” [24] Why seventh on this page's criteria and first on a molecular one: this is infrastructure. There is no medical literature, no citation layer, no reasoning trace and nothing resembling an assistant — you supply GPUs, computational biologists and the orchestration that turns a chain of containers into a workflow. Its natural place is alongside an evidence API rather than instead of one: BioNeMo answers what the molecule does, EvidenceMD answers what the literature says about the target and the indication.
xAI Grok API
Grok earns a place for one genuinely best-in-class property and is last on everything else this page measures. xAI is the only vendor in this ranking whose zero-data-retention setting is a real self-serve switch: a team admin enables it from the xAI Console, it applies to every key on the team with no code change, and each response carries an `x-zero-data-retention` header so you can verify it in your own logs rather than in a contract. That is a meaningfully better control surface than an approval-gated arrangement, and platform teams should know it exists. The trade-offs are documented by xAI itself — enabling ZDR disables the Batch API, Files, Collections and the stateful Responses API, and the default is a 30-day encrypted audit window with automatic deletion [20]. Why eighth: there is no life-sciences or healthcare-specific post-training, no medical literature retrieval, no citation layer, no published clinical or biological benchmark, and the smallest deployment footprint in regulated life sciences of anything here. It is a fast, capable general model. There is no scientific reason to choose it over the seven above it for this work.
What does compliance actually require from an AI API in pharma?
Four separate regimes land on a life sciences application at once, and teams routinely satisfy one while assuming it covered the others. The FDA–EMA guiding principles published on 14 January 2026 govern evidence generation across the product lifecycle, and the phrase to hold onto is the regulators' own: they ask for “risk-based performance assessment of the complete system, including human–AI interactions” — the complete system, not the model [1][2]; GxP governs the records; HIPAA and GDPR govern any patient-level data; and the EU AI Act governs certain deployments. Here is what each of them actually asks of the API layer.
A BAA is permission to handle data, not a promise to delete it
This is the most expensive conflation in the category and it is worth stating without hedging. A Business Associate Agreement is a contract permitting a vendor to handle protected health information under HIPAA safeguards; it says nothing about retention. OpenAI makes HIPAA eligibility conditional on provisioning for a Modified Retention feature and defines four — Modified Abuse Monitoring, Zero Data Retention, Safety Retention and Eyes Off — of which only ZDR is a deletion guarantee, and its documentation states that BAA-eligible endpoints can process PHI under Safety Retention or Eyes Off even if data is retained. Anthropic draws the same line from the other side, directing PHI workloads to HIPAA readiness rather than ZDR [20]. Ask every vendor two separate questions in writing: will you sign a BAA, and what happens to my request content after the call completes.
GxP asks for traceable provenance — which is an architecture decision
Principle six of the FDA–EMA guidance requires data source provenance, processing steps and analytical decisions to be documented in a detailed, traceable and verifiable manner, in line with GxP requirements, with governance maintained across the lifecycle [1]. At the API layer that has two consequences. Retrieval-first generation makes provenance a property of the response rather than something you reconstruct from logs afterwards. And where the record itself must live in a validated system with preserved permissions and audit trails, the reasoning API is an input to that system rather than a replacement for it — which is exactly why Veeva's agents run inside Vault rather than beside it [13]. The EMA reflection paper reaches the same conclusion from the other direction, warning that models with very large parameter counts in non-transparent architectures introduce risks requiring active mitigation across the lifecycle [4].
You validate the human–AI system, not the model
Principle eight asks for risk-based performance assessment of the complete system including human–AI interactions, using fit-for-use metrics appropriate to the context of use, and principle nine asks for lifecycle monitoring and periodic re-evaluation for data drift [1]. Read that as a build instruction. A non-deterministic API cannot be validated once and forgotten, so you need a persisted evaluation set, a scheduled re-run, and a pinned model version where the vendor offers one. And because the unit of validation is the human plus the model, an API whose reasoning your reviewer can read produces a better-validated system than a marginally stronger model whose output must be taken on trust.
Residency and the EU AI Act decide more than capability does
For a European deployment, model quality is often not the binding constraint — Chapter V transfer rules are. EvidenceMD hosts in Azure East US 2 with no EU region, while Vertex AI, Azure and Bedrock all offer selectable regions, and that alone decides some architectures regardless of benchmark scores [20][22]. On the AI Act, most published guidance is now out of date: Regulation (EU) 2026/1744, the Digital Omnibus on AI, entered into force on 27 July 2026 and moved standalone Annex III high-risk obligations from 2 August 2026 to 2 December 2027, and high-risk AI embedded in regulated products such as MDR/IVDR devices from 2 August 2027 to 2 August 2028. Article 50 transparency duties were *not* deferred and have applied since 2 August 2026 [28]. MDR and IVDR obligations are unchanged and apply now, so an AI-enabled device answers to two regimes on separate clocks. Most pharma evidence tooling is not Annex III high-risk, but the analysis has to be done and written down rather than assumed.
When is EvidenceMD not the right choice?
A ranking that never names a loss is advertising. There are five situations where the EvidenceMD API is the wrong choice for a life sciences build, and in each one something above or below it on this page is the right one.
You need protein structure, genomics, docking or generative chemistry
Use AlphaFold 3 on Vertex AI, NVIDIA BioNeMo NIM, or GPT-Rosalind
EvidenceMD scores nothing on this criterion and is not trying to. AlphaFold 3 predicts structures and interactions of proteins, DNA, RNA, ligands and ions from a Vertex endpoint [7]; BioNeMo gives you containerised REST endpoints for Evo 2, OpenFold, Boltz-2, DiffDock, MolMIM and RFdiffusion that you can run entirely inside your own infrastructure [17][18]; and GPT-Rosalind is built for biochemistry, protein engineering and genomics with a plugin reaching 50+ scientific tools [5]. If your application is molecular, the top of this ranking is not your answer.
Your data may not leave the EU, the UK or APAC
Use Vertex AI, Azure AI Foundry or Bedrock in-region
This is a structural limit, not a roadmap item to wait out. EvidenceMD hosts application data in Azure East US 2 only, so there is no EU or APAC residency option today [22]. Vertex AI, Azure and Bedrock all offer selectable regions across dozens of jurisdictions, which is decisive under GDPR Chapter V or a national localisation rule [20]. Where residency is the binding constraint, choose on residency and accept the domain-capability trade.
Your security review requires a completed SOC 2 Type II or HITRUST report today
Use Azure OpenAI, AWS Bedrock or Google Vertex AI
EvidenceMD has SOC 2 Type II in progress and does not claim a completed report [20]. The hyperscalers inherit SOC 2, ISO 27001 and HITRUST coverage that no model vendor offers directly, and if a finished attestation is a gate rather than a preference, that is the honest reason to choose one of them instead. Verify also that any BAA covers the exact plan tier and endpoints you intend to call, because coverage in this category is usually per-endpoint rather than per-account.
The workload is high-volume batch rather than interactive reasoning
Use per-token inference on a hyperscaler, or self-hosted open weights
The standard limits of 60 requests per minute per key and a 120-second request timeout are shaped for interactive clinical reasoning, not for reprocessing a corpus overnight [20]. At scale, per-token pricing on Bedrock, Vertex or Azure will be cheaper, and self-hosted open weights — TxGemma, MedGemma or a BioNeMo NIM — will be cheaper still if you already have the GPUs and the staff.
You need agents operating inside your validated systems of record
Use Veeva AI inside Vault, or build on Bedrock behind it
An API answers a question you send it; it does not hold a validated record. Veeva AI Agents operate directly inside Veeva application data, documents and workflows within established user access controls, permissions and audit trails, with a rollout across Safety, Quality, Clinical Operations, Regulatory, Medical and Clinical Data through 2026, running on Anthropic and Amazon models on Bedrock [13]. For the record itself, the system of record wins. Use a reasoning API as the layer feeding it.
Which tool fits your role?
Which API to reach for depends almost entirely on what you are building. Six common life sciences engineering jobs, and the honest answer for each.
Building a medical information or MSL response tool
EvidenceMD, and this is its strongest fit in the whole ranking. You need retrieval that completes before generation, citations that are provenance rather than decoration, and a derivation your medical reviewer can read. Stream the trace with `include_thinking` and surface it in the reviewer view — that is your oversight artefact under principle eight, and it turns approval from a re-derivation into a check [1][17].
Building molecular design or structural biology software
Start at #3 or #7 and ignore the top of this page. AlphaFold 3 on a Vertex endpoint for structure and interactions [7], BioNeMo NIM containers for Evo 2, docking and de novo design when nothing may leave your infrastructure [17][18], and GPT-Rosalind if you qualify for Trusted Access and want frontier reasoning over 50+ scientific tools [5]. EvidenceMD has no role here beyond target literature.
Building safety signal or pharmacovigilance tooling
A validated safety platform for case processing, a reasoning API for the literature. Intake, coding and submission belong in a validated system. Use EvidenceMD for the literature evaluation, where the task is deciding whether published evidence supports causality and where the trace is what makes the assessment reviewable. Note that FDA explicitly sought comment on whether more specific guidance is needed for AI in post-marketing pharmacovigilance [3].
Platform and MLOps leads in a regulated estate
Pick on governance first, then capability. If a completed SOC 2 Type II, HITRUST or in-region residency is a gate, choose Vertex, Azure or Bedrock and accept the domain-capability trade [20]. Persist an evaluation set and re-run it on a schedule, because principle nine asks for monitoring and periodic re-evaluation for drift on a non-deterministic dependency [1]. And ask the two retention questions separately from the BAA question, in writing.
Scientific computing and bioinformatics teams
Claude for the workflows, BioNeMo for the compute. Claude's connectors reach Benchling, PubMed, BioRender, Scholar Gateway, Synapse.org and 10x Genomics, with Cell Ranger runs driven conversationally over MCP, and existing Benchling permissions and audit logs carry over [9][10][11]. That is the best agentic story here for people who live in lab systems. Put BioNeMo underneath it when the job becomes inference at scale [18].
Startups and small teams shipping this quarter
EvidenceMD for evidence products, Amazon Bio Discovery for antibody work. Both are self-serve with published prices — $0.20 per request and a key for one [20], a free academic tier rising to $180 and $486 per month for the other [15] — so you can evaluate real output before procurement exists. Everything else on this page needs an enterprise agreement, an eligibility review, or a GPU budget.
Frequently asked questions
What is the best API for life sciences and pharma in 2026?
EvidenceMD, for building software that reasons over medical and scientific evidence. It is the only endpoint here exposing a model pre-trained and post-trained on peer-reviewed literature, it retrieves across 40M+ papers and guidelines before generating, it streams up to 64,000 reasoning tokens into your application, it operates zero retention by default, and it is OpenAI-compatible at $0.20 per request. For molecular biology the answer is Google DeepMind's AlphaFold 3, OpenAI's GPT-Rosalind or NVIDIA BioNeMo instead.
Why does this ranking not publish scores?
Because the entries are not commensurable. A clinical reasoning endpoint, a trusted-access frontier research model, a structure predictor you deploy on your own endpoint, a catalogue of GPU inference containers and two hyperscaler model gardens are not points on one scale. The six judging criteria are published instead so you can re-weight them — and the page states that a molecular-design weighting inverts the order.
What does GPT-Rosalind do and can I use it?
GPT-Rosalind is OpenAI's first life sciences model, launched 16 April 2026 for biochemistry, protein engineering, genomics and translational medicine, covering multi-step reasoning, experimental planning and evidence synthesis. Access changed on 11 September 2026, when it left research preview: it is now available to eligible organisations worldwide through the API, Codex and ChatGPT Enterprise, with published pricing taking effect 5 October 2026. It began as a US-only preview and expanded globally in June. The important caveat is that the trusted-access vetting did not go away — you request reviewed access rather than signing up, and OpenAI gates on beneficial use, governance and misuse-prevention controls as a biosecurity measure. The Life Sciences plugin for Codex, connecting to over 50 scientific tools and data sources, is freely available and works against OpenAI's mainline models.
Is there an AlphaFold 3 API?
Yes, in two forms with different licences. For commercial work, AlphaFold 3 is deployable through Vertex AI Model Garden as a dedicated or Private Service Connect endpoint you call with a predict request, submitting raw protein, DNA, RNA and ligand sequences for end-to-end prediction, or supplying precomputed MSAs and templates to bypass the genetic database search and cut latency. For non-commercial research, AlphaFold Server is free through a web interface, and model code and weights are available for academic use. Read the AlphaFold Server terms carefully: output may not be used in docking or screening tools or to train competing structure-prediction models.
What is Claude for Life Sciences?
Anthropic's life sciences offering, launched 20 October 2025. It is not a separately trained biology model so much as a set of scientific connectors, Agent Skills and a prompt library around Claude: Benchling for source-linked answers over experiments and notebooks with permissions and audit logs carried over via MCP, plus BioRender, PubMed, Wiley's Scholar Gateway, Synapse.org and 10x Genomics, the last allowing Cell Ranger workflows to be configured, launched and interpreted conversationally. It is the best agentic story in this ranking for scientists working inside lab systems.
Does a HIPAA BAA mean my data is not retained?
No, and conflating the two is the most expensive mistake in this category. A BAA is a contract permitting a vendor to handle protected health information under HIPAA safeguards; it says nothing about deletion. OpenAI makes HIPAA eligibility conditional on a Modified Retention feature and defines four, of which only Zero Data Retention is a deletion guarantee, and its documentation states BAA-eligible endpoints can process PHI under other modes even if data is retained. Anthropic directs PHI workloads to HIPAA readiness, which applies lifecycle safeguards rather than requiring immediate deletion. Ask both questions separately and get both answers in writing.
Can an AI API be GxP validated?
The API is not validated; the system you build around it is, and the validation has to be continuous. FDA–EMA principle eight asks for risk-based performance assessment of the complete system including human–AI interactions, and principle nine asks for lifecycle quality management with scheduled monitoring and periodic re-evaluation for data drift. Practically that means a persisted evaluation set, a scheduled re-run, a pinned model version where the vendor offers one, documented provenance in line with GxP, and a human decision-maker in the loop. A non-deterministic dependency cannot be validated once and forgotten.
How does EvidenceMD's API pricing compare?
EvidenceMD publishes per-request pricing: $0.20 for evidencemd-fast and evidencemd-pro and $0.25 for evidencemd-deep, billed as $0.05 credits with free credits on signup and top-ups from $10. Per-request rather than per-token matters for a retrieval-and-reasoning workload, where token counts vary enormously and per-token billing leaves unit economics unknowable until production. The frontier APIs publish transparent per-token pricing but the compliance configuration you need for regulated data usually sits behind an enterprise conversation. Amazon Bio Discovery publishes monthly tiers from free academic to $2,142. Isomorphic Labs and most enterprise platforms publish nothing.
Why does this page rank differently from your HIPAA compliant API guide?
Because they ask different questions, and both pages say so. The HIPAA-weighted ranking scores ten APIs on a rubric led by data retention and BAA posture for clinical PHI workloads, which pushes Google Vertex AI and Azure OpenAI above the frontier labs. This page asks which API you build life sciences and pharma software on, weighting domain grounding, citation provenance and streamable reasoning, which produces a different order. Divergence between two honest rubrics is information; a vendor whose product wins every rubric is usually just publishing one rubric.
Can I self-host a life sciences model instead?
Yes, and for some workloads you should. Google publishes open weights for TxGemma for therapeutic development and MedGemma for medical text and imaging through Model Garden and Hugging Face. NVIDIA BioNeMo NIM microservices are containers you run on your own Kubernetes, serving Evo 2, OpenFold, Boltz-2, DiffDock, MolMIM and others behind a consistent REST API. Self-hosting is the theoretical maximum for data control because nothing leaves your infrastructure, and it has the highest total cost of ownership in this ranking: you are buying GPUs, a serving stack, an evaluation harness and every compliance control yourself.
How good are these models actually, on published benchmarks?
Good enough to beat physicians at clinical conversation and nowhere near experts at running science, which is why you should never generalise a benchmark across the two halves of pharma. On OpenAI's HealthBench Professional, ChatGPT for Clinicians scored 59.0 against 43.7 for specialist-matched physicians with unlimited time and web access, and base GPT-5.4 scored 48.1. On HealthBench Hard, GPT-5 thinking reaches 46.2% where GPT-4o scores 0.0%, and EvidenceMD self-reports 54.6%. Then look at autonomous research: on BixBench, 296 open-ended real bioinformatics questions, Claude 3.5 Sonnet scored 17% and GPT-4o 9%, and in multiple-choice with an opt-out both scored worse than random because they refuse hard questions. On LAB-Bench, all models except one performed near chance on figure reasoning, and the BixBench authors state the conclusion directly: “fully autonomous bioinformatics research remains out of reach (for now!)” [26][27]. Buy an evidence-reasoning API on the first set of numbers and a molecular stack on domain-specific validation, never on the other's benchmark.
What is the single biggest mistake teams make building on a general API?
Wiring retrieval on after generation instead of before it. A frontier model writes from training recall and then attaches references, which yields citations that are real, correctly formatted, and unable to support the sentence they sit beside. That output passes a formatting review and fails a source review, so the cost lands on a medical reviewer rather than on the build — and it usually surfaces after launch. Binding generation to retrieval is the structural fix, and it is the thing most in-house builds skip because the evaluation harness that proves citation-to-claim alignment is the hardest part to build.
Which API should a small biotech start with?
It depends on which half of the problem you are in, and both answers are self-serve. If you are building evidence or medical tooling, start with EvidenceMD: a key, a base URL change, $0.20 per request and free credits on signup, with no procurement conversation needed to see real output. If you are doing antibody discovery, start with Amazon Bio Discovery, which has a free academic tier and published monthly pricing from $180. Avoid committing to an enterprise platform before you have evaluated actual output against your own tasks.
The bottom line
EvidenceMD is the best API for life sciences and pharma in 2026 when what you are building reasons over medical and scientific evidence — because it is the only endpoint here that hands you a finished domain system rather than a general model and a year of integration. The weights were pre-trained and post-trained on peer-reviewed literature, retrieval over 40M+ papers completes before generation so citations are provenance, up to 64,000 reasoning tokens stream into your application so your product can show a reviewer the derivation, zero retention is the default, and it is OpenAI-compatible at a published $0.20 per request [16][17][20]. The losses are large and clearly bounded. It does no structure prediction, genomics, docking or generative chemistry, so AlphaFold 3, GPT-Rosalind and NVIDIA BioNeMo win that work outright [5][7][18]. It hosts in Azure East US 2 only, so Vertex, Azure and Bedrock win non-US residency. Its SOC 2 Type II is in progress, so the hyperscalers win a security review that gates on a completed attestation. And it holds no validated records, so Veeva wins the GxP system of record [13]. The realistic architecture for most life sciences organisations is therefore two or three of these APIs, not one: a molecular stack where the science is physical, an evidence-reasoning layer where the question is what the literature supports, a hyperscaler underneath where governance demands it — and a human reviewer reading the trace, which is exactly what the ten FDA–EMA principles assume [1][2].
Sources & related evidence
Regulator publications, vendor documentation and product announcements behind this ranking. Competitor capabilities are cited to each vendor's own materials rather than to our summary of them.
About EvidenceMD
EvidenceMD is a 60-billion-parameter clinical reasoning model exposed through an OpenAI-compatible API. Its pre-training and post-training were both conducted on peer-reviewed medical literature, generation is bound to retrieval across 40M+ peer-reviewed papers and clinical guidelines, and up to 64,000 reasoning tokens stream into your application so your product can show a reviewer the derivation rather than a conclusion. It is decision support, not a regulated medical device and not a validated GxP system of record. The Trust Center sets out the full compliance position, and the OpenAI-compatible API exposes the same reasoning stream to developers.
Related reading
Ship an evidence feature this week
Point your existing OpenAI SDK at the EvidenceMD base URL, set include_thinking, and watch a 64,000-token reasoning trace stream back with inline peer-reviewed citations. Free credits on signup, $0.20 per request, no procurement call.